

THE LANCET

Child & Adolescent Health

Supplementary appendix

This appendix formed part of the original submission. We post it as supplied by the authors.

Supplement to: Aguilera-Alonso D, Alonso-Cadenas JA, Roguera-Sopena M, Lorusso N, San Miguel LG, Calvo C. Monkeypox virus infections in children in Spain during the first months of the 2022 outbreak. *Lancet Child Adolesc Health* 2022; published online Sept 1. [https://doi.org/10.1016/S2352-4642\(22\)00250-4](https://doi.org/10.1016/S2352-4642(22)00250-4).


Supplementary appendix

Appendix 1: Supplementary Figure S1 page 1

Appendix 2: Supplementary Table S1 page 2

Appendix 3: Data management and Ethics page 4

Supplementary Figure S1. Cases with laboratory-confirmed monkeypox infection in Spain during the 2022 monkeypox outbreak. The number of cases under 18 years of age in each period is listed above each column. The last week of the figure is incomplete, and late reporting could explain the lower number of cases during that period. Total number of cases obtained from the European Centre for Disease Prevention and Control (ECDC), updated on August 9, 2022.



Supplementary Table S1. Cases under 18 years of age with laboratory-confirmed monkeypox virus infection in Spain from April 26, 2022, to August 3, 2022, sorted by age.

	Case 1	Case 2	Case 3	Case 4	Case 5	Case 6	Case 7
Date of diagnosis	19/7/22	21/7/22	25/7/22	17/6/22	25/7/22	29/7/22	1/8/22
Age	7 months	10 months	13 months	3 years	13 years	13 years	13 years
Gender	Male	Female	Male	Female	Male	Male	Female
Country of birth	Spain	Spain	Spain	Spain	Spain	Spain	Spain
Transmission route	Household contact	Household contact	Unknown	Household contact	Contact with contaminated material	Contact with contaminated material	Contact with contaminated material
Setting of infection	Home (parents)	Home (parents)	Unknown	Home (parents)	Piercing studio	Piercing studio	Piercing studio
Specimen of detection*	Skin lesion	Skin lesion	Skin lesion	Skin lesion	Skin lesion	Skin lesion	Skin lesion
Manifestations	Rash	Rash	Rash, fever, vomiting, diarrhoea	Rash and fever	Rash	Rash	Rash
Antiviral treatment	No	No	No	No	No	No	No
Hospitalization	No	No	No	No	No	No	No
Complications	No	No	Superinfection (skin abscess)	No	No	No	No
Secondary cases	No	No	No	No	No	No	No

	Case 8	Case 9	Case 10	Case 11	Case 12	Case 13	Case 14	Case 15	Case 16
Date of diagnosis	25/7/22	16/7/22	20/7/22	22/7/22	25/7/22	2/8/22	11/7/22	20/7/22	22/7/22
Age	15 years	16 years	16 years	16 years	16 years	16 years	17 years	17 years	17 years
Gender	Male	Male	Male	Female	Female	Male	Male	Male	Female
Country of birth	Spain	Spain	Spain	Spain	Spain	Spain	Spain	Spain	Spain
Transmission route	Contact with contaminated material	Sexual close contact	Contact with contaminated material	Contact with contaminated material	Contact with contaminated material	Sexual close contact	Sexual close contact	Contact with contaminated material	Contact with contaminated material
Setting of infection	Piercing studio	Unknown	Piercing studio	Piercing studio	Piercing studio	Unknown	Unknown	Piercing studio	Piercing studio
Specimen of detection*	Skin lesion	Skin lesion	Skin lesion	Skin lesion	Skin lesion	Skin lesion	Skin lesion	Skin lesion	Skin lesion
Manifestations	Rash	Rash, lymphadenopathy and headache	Rash	Rash	Rash, fever and lymphadenopathy	Rash, asthenia, fever, lymphadenopathy and sore throat	Rash, asthenia, lymphadenopathy, headache and myalgia	Rash	Rash, lymphadenopathy and sore throat
Antiviral treatment	No	No	No	No	No	No	No	No	No
Hospitalization	No	No	No	No	No	No	No	No	No
Complications	No	No	No	No	No	No	No	No	No
Secondary cases	No	Unknown	No	No	No	Unknown	Unknown	No	No

*Detected by monkeypox virus or *Orthopoxvirus* generic real-time PCR.

Data management and Ethics

This study involved the use of patient medical data from the National Surveillance Network (RENAVE), which is the official source for public health surveillance activities in Spain. RENAVE follows the mandate of Spanish and international legislation and is hosted by public institutions. Individual informed consent is not required for data to be included in RENAVE, and all data are pseudonymised, meeting all considerations regarding personal data protection. As this work is in line with alert, response and surveillance activities, no explicit ethics assessment was required. Further information can be found on this website:

<https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Paginas/Legislacion.aspx>